Literature DB >> 7903297

A novel cytochrome P-450IID6 mutant gene associated with Parkinson's disease.

Y Tsuneoka1, Y Matsuo, K Iwahashi, H Takeuchi, Y Ichikawa.   

Abstract

Genetic polymorphism of the CYP2D6 gene [phenotypically individuals are either poor metabolizers (PM) or extensive metabolizers (EM)] has been reported to be associated with susceptibility to Parkinson's disease. We analyzed CYP2D6 genes from Japanese patients and controls, and found that EM/PM polymorphism is not a suitable marker for populations with a low PM frequency. However, a novel mutant highly associated with Parkinson's disease was discovered. The mutation was located at the HhaI site in exon 6 and changed a conserved amino acid residue, Arg296, to Cys296. The risk factor for the mutant homozygote was 5.56 (95% CI, 1.30-23.82). These results suggest that the HhaI polymorphism in the CYP2D6 gene is a part of the molecular basis of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7903297     DOI: 10.1093/oxfordjournals.jbchem.a124164

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  12 in total

1.  Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes.

Authors:  T Kubota; Y Yamaura; N Ohkawa; H Hara; K Chiba
Journal:  Br J Clin Pharmacol       Date:  2000-07       Impact factor: 4.335

Review 2.  Drug-metabolizing cytochrome P450s in the brain.

Authors:  Sharon L Miksys; Rachel F Tyndale
Journal:  J Psychiatry Neurosci       Date:  2002-11       Impact factor: 6.186

Review 3.  Gene-environment interactions in Parkinson's disease: specific evidence in humans and mammalian models.

Authors:  Jason R Cannon; J Timothy Greenamyre
Journal:  Neurobiol Dis       Date:  2012-07-07       Impact factor: 5.996

Review 4.  Polymorphic cytochromes P450 and drugs used in psychiatry.

Authors:  R T Coutts; L J Urichuk
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

5.  Association of CYP2D6 100 C > T and 2850 C > T polymorphisms with generalized tonic clonic seizures among Indians.

Authors:  C C Soundararajan; A Adhin; M Tripathi; H K Prasad; S Jain; S Vivekanandhan
Journal:  J Neural Transm (Vienna)       Date:  2006-07-13       Impact factor: 3.575

6.  Is there a genetic susceptibility locus for Parkinson's disease on chromosome 22q13?

Authors:  K Wilhelmsen; D Mirel; K Marder; M Bernstein; A Naini; S M Leal; L J Cote; M X Tang; G Freyer; J Graziano; R Mayeux
Journal:  Ann Neurol       Date:  1997-06       Impact factor: 10.422

Review 7.  Cytochrome P450 2D6 and Parkinson's Disease: Polymorphism, Metabolic Role, Risk and Protection.

Authors:  Mohd Sami Ur Rasheed; Abhishek Kumar Mishra; Mahendra Pratap Singh
Journal:  Neurochem Res       Date:  2017-09-04       Impact factor: 3.996

8.  Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers.

Authors:  T Fukuda; I Yamamoto; Y Nishida; Q Zhou; M Ohno; K Takada; J Azuma
Journal:  Br J Clin Pharmacol       Date:  1999-04       Impact factor: 4.335

Review 9.  Neurogenetic diseases: molecular diagnosis and therapeutic approaches.

Authors:  U Muller; M B Graeber
Journal:  J Mol Med (Berl)       Date:  1996-02       Impact factor: 4.599

10.  DNA haplotype-dependent differences in the amino acid sequence of debrisoquine 4-hydroxylase (CYP2D6): evidence for two major allozymes in extensive metabolisers.

Authors:  S Panserat; C Mura; N Gérard; M Vincent-Viry; M M Galteau; E Jacqz-Aigrain; R Krishnamoorthy
Journal:  Hum Genet       Date:  1994-10       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.